HIV coinfection with hepatitis c laboratory findings: Difference between revisions

	HIV coinfection with hepatitis c Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating HIV coinfection with hepatitis c from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
HIV coinfection with hepatitis c laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of HIV coinfection with hepatitis c laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on HIV coinfection with hepatitis c laboratory findings
CDC on HIV coinfection with hepatitis c laboratory findings
HIV coinfection with hepatitis c laboratory findings in the news
Blogs on HIV coinfection with hepatitis c laboratory findings
Directions to Hospitals Treating HIV coinfection with hepatitis c
Risk calculators and risk factors for HIV coinfection with hepatitis c laboratory findings

VisualWikitext

Revision as of 16:26, 7 December 2012

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

References

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{HIV coinfection with hepatitis c}}
-{{CMG}}
-==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
+Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
-{{cquote|
-'''1.''' Anti-HCV testing should be performed in all HIV-infected persons ''(Class I, Level B)''.
-'''2.''' HCV RNA testing should be performed to conﬁrm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease ''(Class I, Level B)''.
-'''3.''' Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy ''(Class I, Level A)''.
-'''4.''' Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients  ''(Class I, Level A)''.
-'''5.''' When possible, patients receiving [[zidovudine]] (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin ''(Class I, Level C)''.
-'''6.''' HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation ''(Class IIa, Level C)''.}}
 ==References==
@@ Line 22: / Line 9: @@
 [[Category:Disease]]
 [[Category:Gastroenterology]]
-[[Category:Needs overview]]
+[[Category:Needs content]]

HIV coinfection with hepatitis c laboratory findings: Difference between revisions

Revision as of 16:26, 7 December 2012

References

Navigation menu